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ABSTRACT 
  γ-Tocopherol (γT) protects against DNA-damaging effects of nitrogen oxides, yet 
its physiologic regulation in vivo is unknown.  Observational studies indicate inverse 
associations of 25[OH]-vitamin D with γT and leptin.  To determine whether vitamin D3 
supplementation alters levels of lipid-soluble micronutrients, serum samples (N=85 
subjects) from a randomized, double-blind, placebo-controlled clinical trial of vitamin D3 
(800 IU) and calcium (2 g) alone and in combination were analyzed for lipid 
micronutrients and specific vitamin D metabolites at baseline and after 6-months of 
supplementation.  Serum 25[OH]-vitaminD3 levels increased 55% (P < 0.0001) and 48% 
(P = 0.0005), whereas 25[OH]-vitaminD2 levels decreased by 48% (P = 0.26) and 21% (P 
= 0.36) in the vitamin D3 and vitamin D3 plus calcium groups, respectively.  At baseline, 
γT levels were inversely associated with 25[OH]D (r = -0.31, P = 0.004).  With vitamin 
D3 plus calcium treatment, serum α-tocopherol decreased 14% (P = 0.04), while similar 
changes in γT (19% decrease, P = 0.14) were observed.   No significant effects were 
observed for D3 supplementation on leptin or retinol levels.  These results are consistent 
with the hypothesis that vitamin D3 +/- calcium affects serum tocopherol and 25[OH]D2 
levels, however, studies utilizing larger populations are warranted. 
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INTRODUCTION 
The tocopherols are important agents in preventing cellular oxidative damage, and 
are postulated to protect against the development of cancer and other aging-related 
diseases (1, 2).  Although α-tocopherol (αT) has the highest level of vitamin E bioactivity 
amongst the tocopherols (3) and, consequently, has been the target of most animal and 
epidemiologic research over the years, more recent findings have pointed to the other 
tocopherols, particularly γ-tocopherol (γT), as playing significant roles in inhibiting the 
development of cancer in animal models (2).  Epidemiological evidence, while limited, 
also suggests an inverse association of γT with certain cancers (4, 5) and heart disease 
(6).  γT has been identified as a key cellular antioxidant that specifically blocks damage 
to cells resulting from the enzymatic production of nitric oxide (NO), a mediator of 
inflammation through its oxidation products (7, 8).  Conversely, αT appears to be a 
primary reactant against cellular oxygen-based oxidants, but lacks anti-inflammatory 
activity (9).  Together the two forms of tocopherol protect cells from the major forms of 
endogenous oxidative assault.  The assumption that serum tocopherol levels reflect 
dietary intake is valid only in cases of severe deficiency or heavy supplement use (10); 
hence, the physiologic determinants of serum levels of the tocopherols may be key to 
elucidating their potential functions for either reducing/promoting disease or serving as 
markers of risk.  In particular, serum levels of γT appear to be unrelated to dietary intake 
and may reflect to a large extent the level of chronic inflammation as suggested by its 
positive associations with circulating C-reactive protein and urinary isoprostane (11), 
thereby complicating the epidemiologic interpretation of its associations with diseases.   
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Vitamin D is associated with lower risk for cancer, primarily colorectal (12, 13), 
cardiovascular disease (14), and all-cause mortality (15).  Vitamin D deficiency may 
result in chronic inflammation and decreased immune function (16).  It was observed 
previously that serum 25(OH)-vitamin D (25[OH]D, as the sum of 25[OH]D2 + 
25[OH]D3), and γT were significantly inversely associated with one another and in turn 
associated with all-cause mortality (11).  In that same study, a positive association of 
circculating αT with 25[OH]D was observed.  It was hypothesized that deficiency of 
vitamin D may lead to a state of chronic inflammation resulting in elevated γT levels 
which protect against NO-mediated damage, thereby compensating against some of the 
deleterious consequences of vitamin D deficiency.  However, in previous studies (17, 18), 
it was also observed that both body mass index (BMI) and leptin (an adipocytokine 
produced predominantly by white adipose tissue) were inversely associated with serum 
25[OH]D and positively associated with γT levels.  This suggests the possibility that the 
inverse association between γT and 25[OH]D may be incidental to obesity and not 
directly related to vitamin D status.  Also, there is in vitro evidence supporting regulation 
of leptin by vitamin D (19) and regulation of vitamin D by leptin (20), but definitive in 
vivo evidence is lacking. 
Circulating retinol levels are reported to rise in winter and decline in summer, 
inverse to changes predicted for vitamin D (7), suggesting a possible interaction and/or 
compensation between vitamins D and A.  Research evidence in animals (21) and 
humans (22) suggests that high doses of vitamin A may antagonize vitamin D actions.  
Support for an interaction between vitamins A and D is also provided in a recent nested 
case-control study of colorectal cancer by Jenab, et al. (23) where the retinol-colon 
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cancer association was inverse among individuals with low vitamin D but direct among 
individuals with higher vitamin D levels.  To our knowledge, there are no published data 
on the influence of vitamin D supplementation on circulating vitamin A and tocopherol 
levels.  The primary objective of the current study was, therefore, to examine the effects 
of vitamin D3 and/or calcium supplementation on changes of serum levels of αT, γT, 
retinol (vitamin A), and leptin levels.  In addition, we sought to determine whether 
supplemental D3 and calcium, alone or in combination, affect serum levels of specific 
vitamin D metabolites such as 25[OH]D2, 25[OH]D3, and vitamins D2 and D3.   
 
METHODS 
Study population and protocol: This study utilized stored serum samples from a 
previous pilot, randomized, double-blind, placebo-controlled, 6-month clinical trial that 
used a 2 x 2 factorial design to test the effects of calcium and/or vitamin D on biomarkers 
of risk for colon cancer (24).  In brief, 92 adults aged 30 to 75 years, in general health, 
capable of informed consent, with a history of at least one pathology-confirmed 
adenomatous colorectal polyp within the past 36 months, no contraindications to calcium 
or vitamin D supplementation or rectal biopsy procedures and no medical conditions, 
habits, or medication usage that would otherwise interfere with the study, and taking  ≥ 
80% of their study pills during 1-month placebo run-in period, were recruited from the 
patient population attending the Digestive Diseases Clinic at the Emory Clinic, Emory 
University.  The Institutional Review Boards of Emory University and the University of 
Hawaii approved the current study protocol.  
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 At baseline, eligible participants were randomly assigned to the following four 
treatment groups:  a placebo control group (placebo), a 2.0 g elemental calcium (as 
calcium carbonate in equal doses twice daily) supplementation group (calcium), an 800 
IU [as 400 IU cholecalciferol (D3) twice daily] vitamin D3 supplementation group 
(vitamin D3), and a calcium plus vitamin D3 supplementation group (calcium plus 
vitamin D3) taking 2.0 g elemental calcium plus 800 IU vitamin D3 daily.  The 
corresponding supplement and placebo pills were identical in size, appearance, and taste.  
The placebo was free of calcium, magnesium, vitamin D, and chelating agents.  
Additional details on the rationale for the doses and forms of calcium and vitamin D3 
supplements were described previously (24).     
 The treatment period was 6 months, and participants attended follow-up visits at 2 
and 6 months after randomization and were contacted by telephone between the second 
and final follow-up visits.  Pill-taking adherence was assessed by questionnaire, 
interview, and pill count.  Participants were instructed to remain on their usual diet and 
not take any nutritional supplements not in use on entry into the study.  Blood was 
collected at baseline (randomization) and at study completion (6-month follow-up), and 
diet was assessed with a semi-quantitative food frequency questionnaire (25).  A total of 
85 subjects (21-22 per group) completing the study with blood samples at baseline and at 
six months were available for analysis and utilized in the current study. 
 
Sample analyses:  Serum levels of vitamins D2 and D3, 25[OH]D2, and 25[OH]D3 were 
analyzed using liquid chromatography orbitrap mass spectrometry.  An aliquot of 0.3 mL 
serum was mixed with 0.3 mL methanol, 2 mL hexane, and 15 µL of a methanolic 
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solution containing D3-d6 and 25[OH]D3-d6 (Medical Isotopes, Pelham, NH).  After 
centrifugation, the hexane layer was removed and subsequently evaporated to dryness 
under a stream of nitrogen.  The residue was reconstituted in 0.15 mL methanol and 20 
µL extract was injected into HPLC (model Accela, ThermoFisher, San Jose, CA).  
Separation was conducted on an Ascentis Express C18 column (150 x 3.0 mm i.d., 2.7 
µm; Supelco, Park Bellefonte, PA) and a pre-filter cartridge (2.1 mm i.d., 0.2 µm; 
ThermoFisher, San Jose, CA) with a mobile phase gradient consisting of 
isopropanol/water/methanol/acetonitrile (0/12/ 69.6/18.4 [vol/vol/vol] for 3.5 min, 
0/0/60/40 for 4.5 min, 55/0/10/35 for 6 min, and 0/12/69.6/18.4 for 5.1 min, 
successively).  The flow rate was kept at 0.7 mL/min.  After electrospray ionization, the 
orbitrap mass spectrometer (model Exactive, ThermoFisher, San Jose, CA), with exact 
mass determination to five decimal places, was operated at the following masses for 
quantitating the respective vitamin D metabolites:  m/z  379.336/ 380.339/ 397.346/ 
398.349 for D2, m/z 367.336/ 385.346/ 386.349 for D3, m/z 377.320/ 378.324/ 395.330/ 
396.335/ 413.341/ 414.341 for 25[OH]D2, m/z 365.320/ 366.323/ 383.330/ 384.333/ 
401.341/ 402.341 for 25[OH]D3, m/z 391.383 for D3-d6, and m/z 389.368 for 25[OH]D3-
d6. 
Serum concentrations of total 25[OH]D were also measured according to the 
manufacturer’s directions using an immunoassay kit (Immunodiagnostic Systems, Ltd. 
Fountain Hills, AZ).  Leptin immunoassay kits purchased from R&D System 
(Minneapolis, MN) were used to analyze serum leptin levels according to the 
manufacturer's instructions.  Serum retinol and tocopherol levels were analyzed by HPLC 
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with pre-column electrochemical oxidation and post-column UV detection, as previously 
described in detail (11, 26).   
 
Statistical Analysis: Treatment groups (placebo, calcium, vitamin D3, calcium plus 
vitamin D3) were assessed for comparability of characteristics at baseline and at final 
follow-up by Fisher’s exact test for categorical variables and ANOVA for continuous 
variables.  
 Primary analyses were based on assigned treatment at the time of randomization 
regardless of adherence status (intent-to-treat analysis).  Means of outcome variables 
were calculated for each treatment group for the baseline and 6-month follow-up visits.  
Treatment effects were evaluated by assessing the differences in the outcome variables 
from baseline to the 6-month follow-up visit between participants in each active 
treatment group and the placebo group by a repeated-measures linear MIXED effects 
model.  The model included the intercept, follow-up visit effects (baseline and follow-
up), and interactions between treatment groups and the follow-up visit effect (the 
absolute treatment effect).  To provide perspective on the magnitude of the treatment 
effects, we also calculated proportional treatment effects, defined as (absolute treatment 
effect / treatment group baseline) x 100% (e.g., a proportional effect of 56% would mean 
a 56% increase in the active treatment group relative to the placebo group).  Because the 
treatment groups were balanced on potentially influential factors (participant 
characteristics and dietary intakes of certain nutrients) at baseline, no adjustment was 
made for other covariates in the primary intent-to-treat analyses.  Spearman correlation 
was used to assess the associations between analyte levels.  SAS software (SAS Institute, 
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Cary, North Carolina) was used for analyses.  All tests were two sided, and P < 0.05 was 
considered statistically significant. 
 
RESULTS 
Characteristics of study participants 
 The four treatment groups did not differ significantly with respect to participant 
characteristics measured at baseline (Table 1, based on a total of 92 originally 
randomized subjects).  The mean age of participants was 60.5 ± 7.9 (SD) years, 64% 
were men, 71% were white, 88% were current non-smokers, and 82% were overweight or 
obese.  The mean values of BMI were 30.1 ± 6.1 kg/m2 at baseline and 30.2 ± 6.2 kg/m2 
at 6-month follow-up (p = 0.38).   Baseline values of γT for 30.6 % of the 85 subjects 
who completed the trial were considered hyper-gammatocopherolemic (11) with levels > 
2.5 µg/ml.  This was comparable to what was observed previously for male control 
subjects in another study (11), where 28.9% were found to have elevated γT.  After the 
six-month intervention 22.4% of the 85 subjects in all four treatment groups were 
observed to be hyper-gammatocopherolemic.  Adherence to visit attendance averaged 
92% and did not differ significantly among the four treatment groups.  On average, at 
least 80% of pills were taken by 93% of participants at the first follow-up visit and 84% 
at the final follow up visit.  There were no treatment complications.   
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Effects of supplemental calcium and/or vitamin D3 on specific serum vitamin D 
metabolites.  
 Serum specific vitamin D measures are shown in Table 2.  At baseline, there were 
no significant differences between the four treatment groups in 25[OH]D3, 25[OH]D2, 
and vitamins D3 and D2 levels.  Serum levels of 25[OH]D3 significantly increased by 
approximately 50% at the end of 6-month’s follow-up in the treatment groups that 
received supplemental D3 alone (P < 0.0001) or combined with calcium (P = 0.0005) 
relative to placebo.  There were no statistically significant treatment effects on serum 
levels of 25[OH]D2, vitamin D2, or vitamin D3.  However, relative to placebo, 25[OH]D2 
levels decreased by 48% in the supplemental vitamin D3 group (P = 0.26) and 21% in the 
vitamin D3 plus calcium group (P = 0.36), and 16% higher (P = 0.75) in the calcium 
group after six months.  Serum vitamin D3 levels were not significantly changed relative 
to placebo after supplementation, but were observed to be 34% higher (P = 0.08) among 
individuals supplemented with D3 alone and 17% higher (P = 0.36) in those who received 
D3 plus calcium, relative to baseline. 
 
Effects of supplemental calcium and/or vitamin D3 on serum tocopherols, retinol, and 
leptin. 
  Baseline serum levels of 25[OH]D were significantly inversely correlated with 
γT (r = -0.31, P = 0.004) but were not significantly correlated with αT (r = 0.12, P = 
0.29).  Serum αT and γT levels were not significantly correlated with each other at 
baseline (r = -0.10, P = 0.38). 
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 Mean serum levels of αT, γT, retinol, and leptin for each group at baseline and 
after six months supplementation are shown in Table 3.  While both vitamin D3 
intervention groups had lower γT levels after six months supplementation with vitamin 
D3 relative to baseline, the absolute treatment effect, which also factors in changes in the 
placebo group, were not statistically significant.  Serum αT and γT levels decreased by 
14% (P = 0.04) and 19% (P = 0.14), respectively, in the calcium plus vitamin D3 group 
relative to placebo when analyzed by absolute treatment effect.  There also appeared to 
be a trend for decreasing serum γT levels as indicated by the relative treatment effects 
(calcium group, -3%, P = 0.85; vitamin D3 group, -8%, P = 0.57; calcium plus vitamin D3 
group, -19%, P = 0.14).  As shown in Figure 1, when all vitamin D3-supplemented 
subjects were combined and stratified by baseline 25[OH]D level, there was a clear trend 
toward both increased 25[OH]D and lower serum γT levels after six months of vitamin 
D3 treatment across all quartiles, consistent with the inverse association between serum 
γT and 25[OH]D observed both at baseline and after treatment.   
Although lower retinol levels were observed in supplemental D3 +/- calcium-
treated subjects (Table 3), slightly higher retinol levels were observed in subjects treated 
with vitamin D3 alone, indicating no consistent effect of vitamin D3 supplementation on 
retinol.  In the current study 82% of study participants were overweight or obese and their 
weight remained constant over the 6-month experimental period (mean BMI:  baseline, 
30.1 ± 6.1 kg/m2; 6 months, 30.2 ± 6.2 kg/m2).  Baseline leptin values were highly 
correlated with BMI (r = 0.67, P < 0.0001) and significantly correlated with γT (r = 0.24, 
P = 0.03).  No significant changes in leptin levels (Table 3) were observed for any 
treatment group, consistent with the stable BMI levels observed.  The calcium + vitamin 
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D3 group, relative to the other treatment groups, did have borderline elevated leptin levels 
at baseline, which remained high at the six-month follow-up.   
 
DISCUSSION 
Several studies (27-29) reported that supplemental D2 or D3 increases circulating 
levels of 25[OH]D, an indicator of vitamin D nutritional status in humans, and vitamin D3 
is considered to be the more biologically potent form (30, 31).  As expected, this 
randomized clinical trial of daily supplementation with 800 IU vitamin D3 demonstrated 
that increased serum 25[OH]D3 was responsible for the increase in total 25[OH]D 
observed, but vitamin D3 supplementation did not increase 25[OH]D2 levels.  Indeed, 
lower 25[OH]D2 levels were observed suggesting that a possible competing effect on 
25[OH]D2 should be considered in larger studies of D3 supplementation.  In contrast, 
Holick et al. (27) reported that a 1,000 IU dose of supplemental D2 daily for 11 weeks did 
not negatively affect serum 25[OH]D3 levels.  In the present study, using a modest dose 
of D3 (800 IU per day) in the upper range of current official recommendations (32), 
serum levels of 25[OH]D3 increased by approximately 8 ng/ml in individuals who 
received D3 +/- calcium, going from an average of approximately 19 ng/ml (inadequate) 
to approximately 27 ng/ml (near sufficient), whereas mean 25(OH) D2 levels were lower 
after supplementation by approximately one ng/ml in those supplemented with D3 +/- 
calcium.  Vitamin D3, synthesized in the skin under the influence of solar ultraviolet 
light, is the primary source of vitamin D (other than dietary supplements) for most people 
(33).  Thus, the clinical significance of reduced circulating 25[OH]D2 levels due to 
vitamin D3 supplementation may not be relevant since 25[OH]D3 (derived from D3) is 
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considered the predominant form in the circulation; nevertheless, the physiological 
significance of 25[OH]D2 independent of 25[OH]D3 remains unclear at present. 
Results from the present pilot study support, but do not prove, the hypothesis that 
vitamin D3 supplementation, alone or in combination with calcium, alters serum αT and 
γT levels.  At baseline, serum 25[OH]D and γT were significantly inversely correlated, 
whereas αT was positively, but not statistically significantly, associated with 25[OH]D, 
consistent with previously published findings (11).  Lower αT and a trend towards lower 
γT were observed after D3 supplementation (Table 3 and Figure 1); however, the sample 
size was too small to detect the estimated absolute treatment effect on γT.  The 
demonstration of a possible causal relationship between sub-optimal 25(OH) D3 levels 
and circulating γT is particularly important, as the means by which γT levels are 
regulated physiologically are not known.  Given the observed associations between 
25(OH) and γT in this and a previous study (11), vitamin D would be predicted to 
account for approximately 5-20% of the variability in circulating γT if a causal 
relationship existed.  The observed borderline significant changes in response to D3 
supplementation (about 12% overall for the combined groups receiving D3) are consistent 
with such a postulated effect, where supplementation with D3 changed vitamin D status 
from deficiency to near adequate levels.  As in a previous study (11), we also observed a 
significant inverse association between 25[OH]D and γT at baseline and after 
supplementation (Figure 3).  The previous observation that this inverse correlation was 
strongest in African Americans and Latinos (11) takes on greater significance in light of 
the current study and suggests that future efforts might be targeted towards a specifically 
vitamin D-deficient population to fully establish whether there is a causal relationship.  
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The previously reported positive correlation of serum αT and 25[OH]D levels (11) was 
also observed in the baseline levels of the participants in the present study (although it 
was not statistically significant); however, vitamin D3 supplementation in the current 
study clearly did not increase circulating αT, as αT levels were significantly lower after 
supplementation in the calcium plus vitamin D3 group.  The positive association for αT in 
the previous study may have been due to the multi-ethnic population studied (11) and/or 
the confounding effects of αT supplementation in that population.  This effect was not 
tested in the current study, as there was no significant correlation between αT and γT 
levels at baseline and no αT was provided as a supplement.  Another explanation may be 
that vitamin D deficiency does indeed cause both tocopherols to rise but αT is depleted to 
a greater extent because of the increased oxidation associated with an inflammatory state 
resulting from vitamin D deficiency.  Evidence for such a mechanism is provided in cell 
culture studies where it was observed that inducing oxidative stress causes γT to rise in 
relation to αT; however, if NO synthesis and a corresponding oxidative assault are 
inhibited, then levels of both tocopherols would rise in response to the inflammatory 
trigger (34).  In a separate analysis of the subjects used in the current study (35), 
biomarkers of inflammation were observed to be lower in vitamin D3-treated subjects, 
consistent with the hypothesis that tocopherols were lower as a result of decreased 
inflammation.  The potentially interactive effects of calcium with vitamin D3 seen for 
tocopherols in the present study are intriguing and warrant further investigation to 
determine the mechanism of action.  
 Previous reports indicated that serum 25[OH]D levels were inversely associated 
with BMI (17, 18), suggesting a possible influence of obesity and its associated effects on 
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leptin on metabolic pathways of vitamin D and /or its precursors.  In the current study the 
majority (82%) of study participants were overweight or obese and their weight remained 
constant over the 6-month experimental period (mean BMI:  baseline, 30.1 ± 6.1 kg/m2; 6 
months, 30.2 ± 6.2 kg/m2), as did serum leptin levels (Table 3).  Therefore, our results 
suggest that:  1) supplementing 800 IU of vitamin D3 daily for 6 months effectively 
raised vitamin D status via increased circulating 25[OH]D3 levels in this middle 
aged/elderly, overweight study population; 2) supplemental D3 may depress 25[OH]D2 
levels (46% in the vitamin D3 group and 21% in the calcium plus vitamin D3 group); and 
3) supplemental 25[OH]D3 had no significant impact on serum leptin levels.  In addition, 
we found no evidence for increased levels of circulating vitamin D3 in overweight 
individuals, indicating that weight and/or leptin did not significantly affect the conversion 
of circulating vitamin D3 to 25[OH]D3.  
The strengths of the present study included the randomized, double-blind, 
placebo-controlled trial design; high protocol adherence by study participants; and that it 
is the first study to examine both the independent and combined effects of calcium and 
vitamin D3 on serum antioxidant micronutrients and specific vitamin D metabolites.  
Limitations of the current study included the relatively small sample size in each 
treatment group and the high BMI levels of most subjects.  However, the findings from 
this pilot study are nevertheless novel, consistent with previous observational and cell 
culture data that point to a possible causal relationship between vitamin D deficiency and 
circulating tocopherol levels, and provide important data for the future designs of studies 
to assess the effects of vitamin D3 supplementation on biochemical and nutritional 
parameters. 
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In summary, in addition to the statistically significant increase in serum 
25[OH]D3 and αT levels and a significant baseline association between 25[OH]D and γT, 
the current results suggest that a modest dose of 800 IU of supplemental vitamin D3, 
alone or in combination with 2 g of elemental calcium daily for 6 months, may affect 
circulating 25[OH]D2 and γT levels as well, but appears to have no appreciable effects on 
retinol or leptin levels.  The current study cannot rule out the possibility that significantly 
higher levels of 25[OH]D might impact retinol levels since vitamin D levels were 
generally low in the study population and the intervention raised circulating levels only 
moderately.  Recommendations for optimal vitamin D levels in nutrition remain 
controversial and many authorities recommend substantially higher levels clinically for 
disease prevention (36, 37) which may have additional impacts on lipid and inflammatory 
biomarkers.  No evidence was found for leptin blocking the conversion of D3 to 
25[OH]D3 in vivo or for reductions in leptin levels by vitamin D3 supplementation.  
Future larger clinical trials are needed to confirm these observations and to explore the 
effects of higher doses of vitamin D +/- calcium on physiologically relevant antioxidants 
and vitamins. 
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Table 1.  Selected baselinea characteristics and dietary intakes of the study participants (n = 92). 
 
 Treatment Group  
 Placebo 
(n = 23) 
Calcium 
(n = 23) 
Vitamin D3 
(n = 23) 
Calcium +Vitamin D3 
(n = 23) 
Pb 
Characteristics      
  Age, y 58.5 (8.2) 61.9 (8.2) 60.2 (8.1) 62.1 (7.5) 0.39 
  Men (%) 70 70 70 70 1.00 
  White (%) 74 83 65 61 0.39 
  College graduate (%) 65 61 57 44 0.53 
  Current smoke (%) 13 9 13 13 0.96 
  Take multivitamin (%) 30 30 26 39 0.86 
  Body mass index, kg/m2 30.6 (7.2) 29.4 (5.5) 28.9 (5.6) 31.6 (6.0) 0.44 
  Waist to hip ratio 0.93 (0.08) 0.92 (0.09) 0.92 (0.10) 0.98 (0.11) 0.17 
Mean dietary intakes      
   Energy, kcal/d 1,596 (528) 1,788 (691) 1,848 (821) 1,845 (752) 0.59 
   Calcium, mg/dc 618 (308) 746 (335) 843 (526) 824 (714) 0.41 
   Vitamin D, IU/dc 277 (230) 336 (202) 360 (317) 415 (316) 0.40 
   Fat, g/d 67 (32) 72 (35) 70 (32) 74 (28) 0.59 
   Alcohol, g/d 9 (14) 11 (15) 14 (18) 10 (20) 0.84 
 
a Data are given as mean (SD) unless otherwise specified. 
b By Fisher’s exact χ2 test for categorical variables or ANOVA for continues variables.  
c Diet plus supplements. 
Table 2.  Serum levels of specific vitamin D measurements at baseline and after 6 months of treatment.  
 
Analyte 
    Treatment Group 
Baseline 6-month Follow-up Absolute 
Rx Effectb 
Proportional 
Rx Effectc 
(%) 
 N Mean (SE)a Pd N Mean (SE)a Pd Mean (SE)a Pd  
25(OH)D3  (ng/mL)          
    Placebo 20 18.8 (1.9)  21 17.2 (1.9)  0  - 
    Calcium 21 23.4 (1.9) 0.10       21 22.5 (2.0) 0.06 0.8 (2.5) 0.74   3.4 
    Vitamin D3 21 19.4 (1.9) 0.84 21 28.3 (2.0) 0.0001 10.7 (2.4) <0.0001 55.2 
    Calcium + Vitamin D3 21 18.8 (1.9) 0.98 18 26.0 (2.0) 0.002 9.0 (2.5)    0.0005 47.9 
25(OH)D2  (ng/mL)          
    Placebo 20 2.5 (1.3)  21 2.4 (1.3)  0  - 
    Calcium 21 1.9 (1.3) 0.76 21 2.1 (1.4) 0.89 0.3 (1.0) 0.75  15.8 
    Vitamin D3 21 2.3 (1.3) 0.93 21 1.2 (1.3) 0.52 -1.1 (1.0) 0.26 -47.8 
    Calcium + Vitamin D3 21 4.3 (1.3) 0.35 18 3.3 (1.4) 0.64 -0.9 (1.0) 0.36 -20.9 
Vitamin D3  (ng/mL)          
    Placebo 20 13.2 (1.5)  21 12.3 (1.6)  0  - 
    Calcium 21 12.7 (1.5) 0.78 21 12.7 (1.7) 0.87 0.9 (2.4) 0.70   7.1 
    Vitamin D3 21 12.5 (1.5) 0.81 21 15.8 (1.6) 0.12 4.2 (2.3) 0.08 33.6 
    Calcium + Vitamin D3 21 12.6 (1.5) 0.76 18 13.8 (1.6) 0.50 2.1 (2.3) 0.36 16.7 
Vitamin D2  (ng/mL)          
    Placebo 20 0.44 (0.16)  21 0.42 (0.16)  0  - 
    Calcium 21 0.31 (0.16) 0.56 21 0.34 (0.17) 0.74 0.06 (0.19) 0.77  19.4 
    Vitamin D3 21 0.64 (0.16) 0.39 21 0.54 (0.17) 0.60 -0.08 (0.19) 0.68 -12.5 
    Calcium + Vitamin D3 21 0.49 (0.16) 0.84 18 0.45 (0.17) 0.91 -0.02 (0.19) 0.91   -4.1 
 
aLeast-squares means are used. 
bAbsolute treatment (Rx) effect = [(treatment group follow-up) – (treatment group baseline)] – [(placebo group follow-up) – (placebo group baseline)]. 
c Proportional treatment (Rx) effect = (absolute treatment effect / treatment group baseline) x 100% (e.g., a proportional effect of 55% would mean that a 55% 
increase in the active treatment group relative to the placebo group). 
d P value for difference between each active treatment group and the placebo group from repeated measures MIXED model. 
Table 3. Serum levels of α-tocopherol, γ-tocopherol, retinol, and leptin at baseline and after 6 months of treatment.  
 
Analyte 
   Treatment Group 
Baseline 6-month Follow-up Absolute 
Rx Effectb 
Proportional 
Rx Effectc 
(%) 
 N Mean (SE)a Pd N Mean (SE)a Pd Mean (SE)a Pd  
α-Tocopherol  (ng/mL)          
    Placebo 21 13.4 (1.0)  21 14.3 (1.0)  0   - 
    Calcium 21 14.3 (1.0) 0.57 21 14.2 (1.1) 0.93 -1.0 (1.1) 0.36  -7.0 
    Vitamin D3 22 13.7 (1.0) 0.87 22 13.5 (1.0) 0.59 -1.0 (1.0) 0.32  -7.3 
    Calcium + Vitamin D3 21 15.5 (1.0) 0.15 21 14.3 (1.0) 0.98 -2.2 (1.0) 0.04 -14.2 
γ-Tocopherol  (ng/mL)          
    Placebo 21 2.38 (0.25)  21 2.39 (0.25)  0  - 
    Calcium 21 1.97 (0.26) 0.24 21 1.93 (0.26) 0.20 -0.05 (0.28) 0.85  -2.9 
    Vitamin D3 22 2.01 (0.25) 0.28 22 1.87 (0.26) 0.14 -0.15 (0.27) 0.57  -7.5 
    Calcium + Vitamin D3 21 2.13 (0.26) 0.47 21 1.74 (0.26) 0.07 -0.40 (0.26) 0.14 -18.8 
Trans Retinol  (ng/mL)          
    Placebo 21 548.4 (33.9)  21 513.5 (34.4)  0  - 
    Calcium 21 597.4 (33.9) 0.31 21 583.1 (36.1) 0.17 20.5 (41.3) 0.62  3.4 
    Vitamin D3 22 573.3 (33.1) 0.60 22 549.7 (34.0) 0.46 11.3 (39.8) 0.78  2.0 
    Calcium + Vitamin D3 21 567.4 (33.9) 0.69 21 500.0 (33.9) 0.78 -32.4 (39.4) 0.41 -5.7 
Leptin   (ng/mL)          
    Placebo 21 17.2 (4.5)  21 17.6 (4.5)  0  - 
    Calcium 21 18.1 (4.5) 0.89 21 17.3 (4.5) 0.97 -1.1 (2.7) 0.68 -6.0 
    Vitamin D3 22 14.9 (4.4) 0.72 22 16.8 (4.4) 0.91 1.5 (2.5) 0.54 10.1 
    Calcium + Vitamin D3 21 26.3 (4.5) 0.15 21 24.1 (4.5) 0.30 -2.5 (2.5) 0.33 -9.5 
 
a Least-squares means are used. 
b  Absolute treatment (Rx) effect = [(treatment group follow-up) – (treatment group baseline)] – [(placebo group follow-up) – (placebo group baseline)]. 
c  Proportional treatment (Rx) effect = (absolute treatment effect / treatment group baseline) x 100% (e.g., a proportional effect of 55% would mean that a 55% 
increase in the active treatment group relative to the placebo group). 
d P value for difference between each active treatment group and the placebo group from repeated measures MIXED model.   
 
 

